These data indicate that anti-CTLA-4 but not anti-PD-1 impacts tumor growth when applied immediately following IRE, but that synergistic effects of anti-PD-1 can be revealed when dosing is timed to match T cell expansion kinetics. The gene discussed is CTLA4; the disease is neoplasm.